Nephrotic syndrome secondary to amyloidosis.
Nephrotic syndrome represents a constellation of symptoms including hyperalbuminuria, hypoalbuminemia, edema formation, hypercholesterolemia, hypertension, hypercoagulopathy, and increased infection risk. The hallmark of this syndrome is proteinuria greater than 3.5 grams per 24 hours, and the clinical features are secondary manifestations of an underlying primary glomerular or systemic disease. The objectives of treatment are threefold: correcting the primary disease, decreasing the symptoms and secondary effects associated with this syndrome, and preventing complications. This article presents a case report of a man diagnosed with nephrotic syndrome secondary to amyloidosis. The clinical aspects of the disease processes, the diagnostic evaluation, the treatment course, and disease management are discussed.
Kneipp
S
S
University of Florida College of Nursing, Gainesville, USA.
Himmelstein
S B
SB
D000328:Adult; D000686:Amyloidosis / Q000150:complications* / Q000175:diagnosis* / Q000628:therapy; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D001706:Biopsy; D003131:Combined Modality Therapy; D003937:Diagnosis, Differential; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008487:Medical History Taking / Q000379:methods; D008558:Melphalan / Q000627:therapeutic use; D009404:Nephrotic Syndrome / Q000175:diagnosis* / Q000209:etiology* / Q000378:metabolism / Q000628:therapy; D010808:Physical Examination / Q000379:methods; D011241:Prednisone / Q000627:therapeutic use; D012017:Referral and Consultation
D000893:Anti-Inflammatory Agents; D018906:Antineoplastic Agents, Alkylating; D008558:Melphalan; D011241:Prednisone